Clinical Practice Guideline
Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction
(Endorsed, August 2011)
The guideline, Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction, was developed by the American College of Physicians and was endorsed by the American Academy of Family Physicians.
- Therapy with a PDE-5 inhibitor should be initiated in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use.
- The choice of a specific PDE-5 inhibitor should be based on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile.
- There is insufficient evidence to recommend for or against the routine use of hormonal blood tests or hormonal treatment.
These guidelines are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute the individual judgment brought to each clinical situation by the patient’s family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These guidelines are only one element in the complex process of improving the health of America. To be effective, the guidelines must be implemented.